Sign up to save your podcasts
Or
Share Reducing Toxicities in Allogeneic Cell Therapies with Orca Bio's Dr. Scott McClellan
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Reducing Toxicities in Allogeneic Cell Therapies with Orca Bio's Dr. Scott McClellan
We love to hear from our listeners. Send us a message.
Orca Bio's CMO, Dr. Scott McClellan, joins Erin Harris on this episode of Cell & Gene: The Podcast to discuss how and why toxicities continue to stymie allogeneic cell therapies. They cover Orca Bio's plan to potentially lowering the risk of GvHD as well as Orca-T, the investigational high-precision allogeneic cell therapy being evaluated in clinical trials for the treatment of multiple hematologic malignancies.
Subscribe to the podcast!
Apple | Spotify | YouTube
Visit my website: Cell & Gene
Connect with me on LinkedIn
View all episodes
By Erin Harris
4.9
3838 ratings
We love to hear from our listeners. Send us a message.
Orca Bio's CMO, Dr. Scott McClellan, joins Erin Harris on this episode of Cell & Gene: The Podcast to discuss how and why toxicities continue to stymie allogeneic cell therapies. They cover Orca Bio's plan to potentially lowering the risk of GvHD as well as Orca-T, the investigational high-precision allogeneic cell therapy being evaluated in clinical trials for the treatment of multiple hematologic malignancies.
Subscribe to the podcast!
Apple | Spotify | YouTube
Visit my website: Cell & Gene
Connect with me on LinkedIn
More shows like Cell & Gene: The Podcast
View all
Freakonomics Radio
32,092 Listeners
Planet Money
30,687 Listeners
Motley Fool Money
3,222 Listeners
The Knowledge Project
2,670 Listeners
Nature Podcast
763 Listeners
HBR IdeaCast
181 Listeners
Immune
277 Listeners
The Readout Loud
324 Listeners
BioCentury This Week
34 Listeners
People I (Mostly) Admire
2,101 Listeners
Raising Health
146 Listeners
Biotech Hangout
19 Listeners
NEJM AI Grand Rounds
56 Listeners
ASGCT Podcast Network
16 Listeners
HBR On Leadership
165 Listeners